Home » Topics » BioWorld Science

BioWorld Science
RSS

TRuE-AD2 pivotal phase III study of ruxolitinib cream meets primary endpoint

Jan. 29, 2020

Blueberry Therapeutics receives IND clearance from the FDA for BB-2603

Jan. 29, 2020

Topline data from phase III VELOS-2 study of HL-036

Jan. 29, 2020

New phase I trial studies monoclonal antibody CIS-43LS against malaria

Jan. 29, 2020

Skin-deep defense may be good enough for arboviruses

Jan. 29, 2020

Mutant TP53 affects fat metabolism

Jan. 29, 2020

Helping hand for protein sorting prevents AD

Jan. 29, 2020

Study suggests direct amino acid toxicity could account for caloric restriction benefits

Jan. 28, 2020

FDA clears INDs for Surface Oncology's antibody candidates SRF-617 and SRF-388

Jan. 28, 2020

Sichuan Kelun-Biotech Biopharmaceutical discloses RORC agonists

Jan. 28, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...